Following a priority review, the Food and Drug Administration has approved Dova Pharmaceuticals' Doptelet for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,